A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

July 6, 2026

Study Completion Date

January 4, 2029

Conditions
Gastrointestinal Cancer
Interventions
BIOLOGICAL

Raludotatug Deruxtecan (R-DXd)

Administered via intravenous (IV) infusion.

Trial Locations (41)

104

RECRUITING

Mackay Memorial Hospital ( Site 0266), Taipei

112

RECRUITING

Taipei Veterans General Hospital ( Site 0262), Taipei

407

RECRUITING

Taichung Veterans General Hospital ( Site 0265), Taichung

1211

RECRUITING

Hôpitaux Universitaires de Genève (HUG) ( Site 0245), Geneva

4031

RECRUITING

Universitaetsspital Basel ( Site 0241), Basel

8091

RECRUITING

Universitaetsspital Zuerich ( Site 0242), Zurich

10002

RECRUITING

National Taiwan University Hospital ( Site 0261), Taipei

10400

RECRUITING

Ramathibodi Hospital. ( Site 0282), Bangkok

10700

RECRUITING

Faculty of Medicine Siriraj Hospital ( Site 0281), Bangkok

14076

RECRUITING

Centre François Baclesse ( Site 0085), Caen

20016

RECRUITING

Sibley Memorial Hospital ( Site 0372), Washington D.C.

22903

RECRUITING

University of Virginia Cancer Center ( Site 0365), Charlottesville

28007

RECRUITING

Hospital General Universitario Gregorio Marañón ( Site 0225), Madrid

28040

RECRUITING

Hospital Universitario Fundacion Jimenez Diaz ( Site 0224), Madrid

33140

RECRUITING

Mt Sinai Comprehensive Cancer Center ( Site 0345), Miami Beach

34298

RECRUITING

Institut Regional du Cancer Montpellier ( Site 0084), Montpellier

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla ( Site 0221), Santander

40447

RECRUITING

China Medical University Hospital ( Site 0267), Taichung

44106

RECRUITING

University Hospitals Cleveland Medical Center ( Site 0369), Cleveland

53792

RECRUITING

University of Wisconsin Carbone Cancer Center ( Site 0348), Madison

59102

RECRUITING

St. Vincent Healthcare Frontier Cancer Center ( Site 0347), Billings

70403

RECRUITING

National Cheng Kung University Hospital ( Site 0263), Tainan City

75013

RECRUITING

Pitie Salpetriere University Hospital ( Site 0082), Paris

94800

RECRUITING

Gustave Roussy ( Site 0081), Villejuif

7500921

RECRUITING

FALP ( Site 0062), Santiago

7501010

RECRUITING

Centro de Estudios Clínicos SAGA ( Site 0064), Santiago

7620002

RECRUITING

Clínica UC San Carlos de Apoquindo ( Site 0066), Santiago

8420383

RECRUITING

Bradfordhill ( Site 0069), Santiago

06510

RECRUITING

Yale New Haven Hospital ( Site 0375), New Haven

07960

RECRUITING

Morristown Medical Center ( Site 0349), Morristown

B7600FZO

RECRUITING

Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001), Mar del Plata

C1431FWO

RECRUITING

Nefra Medical Care - CEMIC Saavedra ( Site 0008), Buenos Aires

S2000CEJ

RECRUITING

Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007), Rosario

F5300COE

RECRUITING

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006), La Rioja

M4N 3M5

RECRUITING

Sunnybrook Research Institute ( Site 0044), Toronto

M5G 1X6

RECRUITING

Princess Margaret Cancer Centre ( Site 0041), Toronto

H2X 3E4

RECRUITING

Centre Hospitalier de l'Université de Montréal ( Site 0042), Montreal

Unknown

RECRUITING

Prince of Wales Hospital ( Site 0122), Hong Kong

RECRUITING

Queen Mary Hospital ( Site 0121), Hong Kong

08916

RECRUITING

Institut Català d'Oncologia (ICO) - Badalona ( Site 0222), Badalona

08036

RECRUITING

Hospital Clinic de Barcelona ( Site 0223), Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY